Cempra Inc. (NASDAQ:CEMP) announced positive topline results from a global, pivotal Phase 3 clinical trial of solithromycin oral capsules or Solitaire-Oral in the treatment of patients with community acquired bacterial pneumonia or CABP. Cempra, Inc. (NASDAQ:CEMP) belongs to Healthcare sector. Its weekly performance is 10.79%. On last trading day company shares ended up $22.89. Cempra, Inc. (NASDAQ:CEMP) distance from 50-day simple moving average (SMA50) is … Continue reading Top Stocks: Cempra, Inc. (NASDAQ:CEMP), Applied Materials, Inc. (NASDAQ:AMAT), Xcel Energy Inc. (NYSE:XEL), Culp, Inc. (NYSE:CFI), Xilinx Inc. (NASDAQ:XLNX)